Synergistic killing of FLT3ITD-positive AML cells by combined inhibition of tyrosine-kinase activity and N-glycosylation

Abstract

// <![CDATA[ $('.header-date').hide();$('#titleAuthors').hide();$('#abstractHeader').hide(); // ]]> Dimitrios Tsitsipatis1, 6, Ashok Kumar Jayavelu1, 7, Jörg P. Müller1, Reinhard Bauer1, Dirk Schmidt-Arras2, Siavosh Mahboobi3, Tina M. Schnöder4, 5, Florian Heidel4, 5, Frank-D. Böhmer1 1Institute of Molecular Cell Biology, CMB, Jena University Hospital, Jena, Germany 2Institute of Biochemistry, Christian-Albrechts-University Kiel, Kiel, Germany 3Institute of Pharmacy, Faculty of Chemistry and Pharmacy, University of Regensburg, Regensburg, Germany 4Innere Medizin II, Hämatologie und Onkologie, Universitätsklinikum Jena, Jena, Germany 5Leibniz Institute on Aging, Fritz-Lipmann-Institute, Jena, Germany 6Current address: Institute of Nutrition, Department of Nutrigenomics, Friedrich-Schiller-University, Jena, Germany 7Current address: Max-Planck Institute of Biochemistry, Department of Proteomics and Signal Transduction, Martinsried, Germany Correspondence to: Frank-D. Böhmer, email: boehmer@med.uni-jena.de Keywords: acute myeloid leukemia, FLT3ITD, tunicamycin, selective cytotoxicity Received: May 11, 2016 Accepted: February 16, 2017 Published: February 28, 2017